Vaxart (VXRT) Competitors $0.44 -0.02 (-3.87%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VXRT vs. RGNX, TRML, ETON, ITOS, RZLT, MBX, RVNC, SLDB, CYRX, and FULCShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include REGENXBIO (RGNX), Tourmaline Bio (TRML), Eton Pharmaceuticals (ETON), iTeos Therapeutics (ITOS), Rezolute (RZLT), MBX Biosciences (MBX), Revance Therapeutics (RVNC), Solid Biosciences (SLDB), CryoPort (CYRX), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Its Competitors REGENXBIO Tourmaline Bio Eton Pharmaceuticals iTeos Therapeutics Rezolute MBX Biosciences Revance Therapeutics Solid Biosciences CryoPort Fulcrum Therapeutics Vaxart (NASDAQ:VXRT) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk. Does the media prefer VXRT or RGNX? In the previous week, REGENXBIO had 1 more articles in the media than Vaxart. MarketBeat recorded 2 mentions for REGENXBIO and 1 mentions for Vaxart. Vaxart's average media sentiment score of 1.46 beat REGENXBIO's score of 1.24 indicating that Vaxart is being referred to more favorably in the media. Company Overall Sentiment Vaxart Positive REGENXBIO Positive Which has more volatility and risk, VXRT or RGNX? Vaxart has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Do insiders and institutionals believe in VXRT or RGNX? 18.0% of Vaxart shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 2.9% of Vaxart shares are held by company insiders. Comparatively, 12.8% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend VXRT or RGNX? Vaxart presently has a consensus target price of $3.00, suggesting a potential upside of 578.73%. REGENXBIO has a consensus target price of $31.63, suggesting a potential upside of 267.09%. Given Vaxart's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vaxart is more favorable than REGENXBIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00REGENXBIO 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has higher earnings and valuation, VXRT or RGNX? Vaxart has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$47.40M2.13-$66.95M-$0.27-1.64REGENXBIO$83.33M5.19-$227.10M-$3.11-2.77 Is VXRT or RGNX more profitable? REGENXBIO has a net margin of -100.62% compared to Vaxart's net margin of -122.63%. REGENXBIO's return on equity of -53.29% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-122.63% -91.89% -38.40% REGENXBIO -100.62%-53.29%-30.84% SummaryREGENXBIO beats Vaxart on 9 of the 16 factors compared between the two stocks. Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.37M$2.42B$5.50B$8.93BDividend YieldN/A1.79%5.38%4.12%P/E Ratio-1.648.9426.2519.86Price / Sales2.13665.31415.14113.78Price / CashN/A154.3736.4957.06Price / Book1.704.548.055.38Net Income-$66.95M$31.16M$3.16B$248.50M7 Day Performance-17.84%0.15%1.78%2.78%1 Month Performance-1.78%8.74%4.74%5.84%1 Year Performance-34.76%2.17%35.81%20.06% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart2.336 of 5 stars$0.44-3.9%$3.00+578.7%-33.2%$101.37M$47.40M-1.64120Positive NewsGap DownRGNXREGENXBIO4.5296 of 5 stars$8.21-2.1%$31.63+285.2%-25.7%$411.81M$156.72M-2.64370Positive NewsTRMLTourmaline Bio2.3444 of 5 stars$15.99-3.3%$49.33+208.5%+24.3%$410.62MN/A-4.9844ETONEton Pharmaceuticals2.653 of 5 stars$14.25+1.7%$29.67+108.2%+312.1%$382.19M$39.01M-79.1720ITOSiTeos Therapeutics3.2094 of 5 stars$9.97+0.2%$15.86+59.0%-33.4%$381.55M$35M-3.2890RZLTRezolute3.1209 of 5 stars$4.46+2.5%$11.83+165.3%+2.6%$381.42MN/A-3.8840High Trading VolumeMBXMBX Biosciences2.3076 of 5 stars$11.41+6.1%$37.50+228.7%N/A$381.37MN/A0.0036RVNCRevance Therapeutics2.705 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500SLDBSolid Biosciences3.5963 of 5 stars$4.87+3.2%$15.10+210.1%-26.6%$377.50MN/A-1.63100CYRXCryoPort2.3313 of 5 stars$7.46+0.7%$11.00+47.5%+14.4%$374.04M$228.38M-3.191,186FULCFulcrum Therapeutics0.326 of 5 stars$6.88-3.1%$6.29-8.6%+8.4%$371.38M$80M-98.27100 Related Companies and Tools Related Companies REGENXBIO Competitors Tourmaline Bio Competitors Eton Pharmaceuticals Competitors iTeos Therapeutics Competitors Rezolute Competitors MBX Biosciences Competitors Revance Therapeutics Competitors Solid Biosciences Competitors CryoPort Competitors Fulcrum Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VXRT) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
